Medication Understanding in MS (MUMS)

April 2, 2026 updated by: University of Nottingham

Home-based Assessment of Medication Understanding and Use in People With Multiple Sclerosis

The goal of this observational study is to learn how people with multiple sclerosis (MS) understand, organise, and use their medicines at home. The study aims to explore how people take their prescribed and non-prescribed medicines, what challenges they experience, and whether any safety issues arise in day-to-day medication use.

Participants will take part in one home visit with trained student researchers. During the visit, researchers will review all medicines and supplements the participant uses, ask about routines and any difficulties, check medication packaging with permission, and ask a brief question about memory. No treatment changes will be made. Information will be reviewed by a senior clinician, and any safety concerns will be shared with the participant's usual healthcare team.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

From outpatient neurology (Nottingham) and rehabilitation medicine (Derby) settings

Description

Inclusion Criteria:

  • Adults aged 18 years and over with a confirmed diagnosis of multiple sclerosis
  • Living in the community (not in residential care)
  • Taking at least one prescribed medication
  • Able to provide informed consent or, for those without capacity to provide informed consent, with a consultee available to provide consultee declaration and provide information during home-based medication review
  • Willing and able to participate in a home-based medication review

Exclusion Criteria:

  • Severe cognitive or communication impairment without a consultee to provide consultee declaration and medication-related information
  • Participants for whom a home visit is deemed unsafe
  • Non-English speakers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
People with multiple sclerosis
Adults with multiple sclerosis living in the community who will receive a single home-based medication review.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Medication Burden (Descriptive)
Time Frame: Baseline
Total number of prescribed and non-prescribed medications and supplements used by each participant, recorded during the home-based medication review. This includes dose, frequency, route, and source of each item. The outcome will be summarised descriptively (counts, means, ranges).
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Medication Adherence (MARS-5 Score)
Time Frame: Baseline
Self-reported adherence measured using the 5-item Medication Adherence Report Scale (MARS-5). Scores range from 5 to 25, with higher scores indicating better adherence. Results will be summarised descriptively.
Baseline
Medication-Related Challenges
Time Frame: Baseline
Proportion of participants reporting difficulties with medication supply, administration, formulation, or perceived effectiveness, based on structured trigger questions. Reported descriptively.
Baseline
Subjective Cognitive Decline (Single-Item Question)
Time Frame: Baseline
("Yes"/"No") to the validated single-item subjective cognitive decline question ("Do you feel you have more problems with your memory than most?"). Used to contextualise medication-taking behaviours. Summarised descriptively.
Baseline
Medication Organisation and Use of Aids
Time Frame: Baseline
Use of medication aids such as dosette boxes, blister packs, phone reminders, or charts. Recorded as present/absent and described using frequencies.
Baseline
Medication Storage and Safety Issues
Time Frame: Baseline
Number and type of potential safety issues identified during the home visit, including expired medicines, duplicate supplies, unmonitored supplements, or storage concerns. Summarised descriptively.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Nottingham

Collaborators

Nottingham University Hospitals NHS Trust
University Hospitals of Derby and Burton NHS Foundation Trust

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 15, 2026

Primary Completion (Estimated)

July 15, 2026

Study Completion (Estimated)

September 1, 2026

Study Registration Dates

First Submitted

March 25, 2026

First Submitted That Met QC Criteria

April 2, 2026

First Posted (Actual)

April 8, 2026

Study Record Updates

Last Update Posted (Actual)

April 8, 2026

Last Update Submitted That Met QC Criteria

April 2, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 26008
  • 368655 (Other Identifier: IRAS)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe